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Abstract
Since the discovery of the Zika virus in Uganda in 1947, diagnostic challenges 
remain, especially when we take into account the epidemiological context of the 
surveyed population. Genetic similarities with other flavivirus are responsible 
for cross-reac tivity during serological evaluation that would often be the only 
resources to confirm the infection in asymptomatic cases or samples collected 
after the short window of viral RNA detection. The importance of Zika virus 
infection diagnosis is undoubtedly useful for pregnant women. This statement 
became evident after 2015 Brazil’s Zika outbreak when a significant increase in 
cases of newborn with microcephaly was observed. Reverse transcriptase real-
time PCR is the most reliable tool for Zika virus infection diagnosis. It detects 
viral RNA in both biological fluids and tissues and contributes to clinical case 
classification for initial description of developmental changes observed in neo-
nates exposed congenitally to Zika virus. In conclusion, advances in serological 
diagnostic are urgent. The safest pathway for these studies requires laborious, 
subjective, and low throughput PRNT evaluations. Consequently, critical public 
health questions remain unanswered: how serum prevalent is the general popula-
tion and pregnant women; can we define risk for congenital Zika syndrome (CZS) 
and Guillain-Barré syndrome; and how to assess vaccine efficacy and long-term 
protection.
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1. Introduction
The Zika virus (ZIKV) belongs to the family Flaviviridae, genus Flavivirus, 
phylogenetically related to the dengue, yellow fever, and West Nile virus [1]. The 
main vector is the Aedes aegypti, hematophagous arthropod well adapted to urban 
living conditions, and for this reason, they are considered as emergent arboviruses, 
transmitted mainly by mosquitoes of the genus Aedes.
Clinically, the infection produces a self-limited febrile disease, whose symptoms 
of the acute phase are fever, headache, myalgia, and cutaneous rash. The virus 
incubation period in humans can range from 3 to 12 days, very similar to other 
arboviruses such as dengue and chikungunya virus. Thus, in regions where there is 
co-infection of these viruses, ZIKV can be sub-notified [2].
The ZIKV is transmitted to humans by the bite of infected female mosquitoes. 
However, other mechanisms of transmission have been described such as sexual 
Biochemical Testing - Clinical correlation and Diagnosis
2
transmission, blood transfusion, and through breastfeeding [3–6]. In addition, the 
presence of ZIKV RNA has been identified already in body fluids such as endocer-
vical or nasopharyngeal swab, saliva, and urine, which highlights other possible 
routes of transmission [7–11]. For example, ZIKV RNA detection in amniotic fluid 
was essential to define fetal infection during vertical transmission [12].
During 1947, ZIKV was originally isolated from the serum of a febrile rhesus mon-
key female, which was used as a sentinel to detect wild yellow fever virus in the Zika 
forest, localized at Uganda [13]. At the same site, the ZIKV was also isolated from a 
mosquito genus Aedes Africanus sample. More than one decade later, the first case of 
ZIKV infection in humans was reported in Uganda, with a detailed clinical descrip-
tion performed by a doctor who described his own infection. He described symptoms 
such as a mild headache, diffuse maculopapular rash, fever, and malaise [14].
Despite this report, ZIKA infections remained relatively unknown until 2007, 
when it occurred as a major outbreak in Micronesia, representing the first evidence 
of virus circulation outside the African continent [15].
The disease spread rapidly across the islands of the Pacific Ocean, and in 
October 2013, initial cases were diagnosed in French Polynesia that culminates with 
a major epidemic [16]. In February 2014, for the first time, ZIKV was detected in 
the Americas, and those cases were reported on Easter Island (Chilean territory 
in the Pacific Ocean), probably related to the outbreak in Micronesia and French 
Polynesia [17].
In Brazil, the first autochthonous transmission was observed in April 2015 in 
patients from Rio Grande do Norte, where the sequence of a fragment of viral enve-
lope protein revealed high identity with ZIKV sequences of the Asian lineage [2]. The 
Ministry of Health of Brazil confirmed the circulation of ZIKV in the country, after 
identifying the viral RNA in 16 serum samples (8 cases from Bahia and the others 
from Rio Grande do Norte). The main symptoms described were arthralgia, edema 
of the extremities, low fever, headache, and retro-orbital pain, conjunctival hyper-
emia, and maculopapular rashes, besides pruritus, dizziness, myalgia, and digestive 
disorder [18]. Approximately 80% of ZIKV infections are asymptomatic or display 
mild-to-moderate symptoms that are self-limited and last between 5 and 7 days [19].
However, before ZIKV outbreak detection, the number of infants born with 
microcephaly in the second half of 2015 increased tremendously, when compared 
with historical reports. This observation was done in the Northeast region of the 
country, and Recife and Salvador and their surroundings were the most severely 
affected cities [18]. Retrospectively, the anamnesis of most parturients revealed 
episodes of febrile illness and exanthematous skin lesions during pregnancy [20]. 
Considering the epidemiological situation, in November 2015, the World Health 
Organization confirmed the relationship between ZIKV infection and congenital 
malformations in neonates, with most cases developing microcephaly and/or 
ventriculomegaly [21, 22].
In addition to CNS malformations due to congenital infections, ZIKV outbreak 
was also associated with increased number of cases of Guillain-Barré Syndrome 
(GBS) in French Polynesia, indicating another CNS-related complication resulting 
from ZIKV infection [23, 24]. In Brazil, severe manifestations associated with ZIKV 
infections were also described such as GBS, transverse myelitis, and meningitis in 
adults [23, 25].
2. Structural properties, genetic context, and evolution
ZIKV particle is composed of a positive-sense, single-stranded RNA about 
10,794 bp in length involved by a protein capsid and surrounding a lipid 
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membrane. The RNA genome presents 5′ and 3′ untranslated regions (UTR), 
flanking a single long open reading frame (ORF) that translates one polyprotein 
(5’-C-prM-E-NS1-NS2A-NS2BNS3-NS4A-NS4B-NS5–3′). After cleavage, the 
polyprotein originates three structural proteins: capsid (C), membrane (M), 
and envelope (E), which are virus particle components, and seven nonstructural 
proteins: NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5, which are involved in 
genome replication, polyprotein cleavage, and evasion of immunologic response 
(Figure 1) [26, 27]. The genome region, encoding flavivirus structural proteins, 
is more susceptible to genome variation when compared to nonstructural coding 
regions. Envelope protein (E), the major virion surface protein, is responsible for 
virus-cell interaction and membrane fusion, therefore being the major target for 
neutralizing antibodies [28]. Three domains were identified in E protein EDI, EDII, 
and EDIII. Karin Stettler and colleagues demonstrated that monoclonal antibod-
ies (mAbs) directed to EDIII domain presented a potent and specific neutralizing 
activity to ZIKV, whereas mAbs directed to EDI/EDII domains partially neutralized 
ZIKV. Additionally, EDI/EDII-specific mAbs displayed higher cross-reactivity with 
dengue virus and enhanced in vitro viral infection, the phenomena described as 
antibody-dependent enhancement (ADE) [29]. This information should be con-
sidered in the development of ZIKV-specific diagnostic tool using antibody-based 
detection.
Figure 1. 
Flavivirus particle diagram. Flavivirus are small spherical enveloped particles. Envelope protein (E), 
responsible for virus-cell interaction and membrane fusion, is the main target for neutralizing antibodies. The 
membrane-associated protein (M) results from the cleavage of the precursor to membrane protein (PrM) 
during virus maturation. Capsid proteins (C) assemble into an icosahedral structure (capsid) and involve the 
virus genomic material (ssRNA+). The genomic RNA coding region is flanked by two untranslated regions 
(5’ UTR and 3’ UTR) and produces a polyprotein that after proteolytic cleavage generates all functional virus 
proteins. Adapted from de Vasconcelos et al. [32].
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Regarding the nonstructural proteins, NS1 glycoprotein is a multifunctional 
virulence factor that intracellularly co-localizes with the virus replication com-
plex. In addition, an infected cell secretes NS1 as a hexameric lipoprotein, and 
several immunomodulatory functions are proposed for this particular protein 
[27]. The secretion of NS1 during acute dengue infection culminates in high 
serum levels of this protein. It occurs mainly during viremic period and encour-
ages the development of NS1-based serologic diagnostic tests during previous 
dengue outbreaks [30]. Recently, one serologic test for ZIKV based on NS1 
reinforces the use of this protein as an acute phase biomarker for flavivirus infec-
tion [31]. The NS5 protein is the largest viral protein whose C-terminal portion 
has RNA-dependent RNA polymerase (RdRP) activity. The polymerase region of 
the protein is generally conserved and can be used for the design of a broad range 
of primers.
Genetic studies using nucleotide sequences derived from the NS5 gene indicated 
three ZIKV lineages: East African, West African, and Asian [1]. However, after 
genome-based phylogenetic analysis, Asian and African strains remained as the 
only two genetic lineages for ZIKV [1]. ZIKV was associated with sporadic human 
infections in Africa and Southeast Asia by the end of the last century and was 
described as a zoonotic pathogen [33]. Due to the first isolation in monkeys and 
mosquitoes, the maintenance of the enzootic ZIKV was first attributed to those two 
groups of animals. However, antibodies have been detected in other animal species 
[26]. The ZIKV ability to switch species can play a special role in virus evolution. 
Especially in virus presenting RNA genome, nucleotide polymorphisms have long 
been noted as an evolutionary mechanism and indicate viral adaptation to the host 
[34, 35]. The mutation rate of ZIKV was demonstrated to be between 12 and 25 
bases per year and corresponds to 0.2% of total ZIKV genome [36]. On top of the 
mutation rate, recombination events also play an important role in virus evolution. 
Fay et al. studying the molecular evolution of ZIKV reported a possible event of 
recombination in E and NS5 genes affecting African samples [28]. Han et al. pro-
pose a recombinant event within Brazilian strain (ZikaSPH2015), French Polynesia 
strain (H/PF/2013), and strain Z1106033 from Suriname [37]. Noteworthy, the 
recombination within Asian strains was not supported by Jun and colleagues when 
196 ZIKV genomes were analyzed [38]. Therefore, further investigation is needed 
in order to accurately correlate genome changes and virulence.
3. Molecular tests (virus detection)
3.1 Quantitative polymerase chain reaction (qPCR)
Quantitative polymerase chain reaction amplification (qPCR) assays have been 
used for laboratory diagnosis of viral infectious diseases, since the sensitivity, 
specificity, and speed of the method allow the rapid detection of viruses in the 
host, human clinical samples, biopsies, and autopsy tissue. Since ZIKV is an RNA 
virus, running an initial reverse transcriptase step followed by a qPCR (RT-qPCR) 
is recommended. This method has been proved to be the most reliable one to 
confirm ZIKV infection during acute phase. Then, the first step for molecular ZIKV 
detection is the RNA isolation from different patient biological samples. When one 
is dealing with tissue samples, it is necessary to mechanically dissociate the freshly 
isolated tissue fragment to further conduct the nucleic acid extraction process. 
Other body fluid samples could be directly processed by an RNA isolation kit before 
viral genome reverse transcriptase reaction followed by amplification using ZIKV-
specific primers and probes.
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One of the limitations of the PCR technique is related to the presence of 
inhibitory substances, such as IgG, hemoglobin, lactoferrin in blood samples, and 
anticoagulants as heparin, that have already been described as PCR inhibitors 
[39]. In urine samples, the most critical component described as PCR inhibitors is 
urea, which can lead to degradation of the polymerase. However, its direct effect 
is dependent on urea concentration in the sample [40]. One way to monitor an 
inhibitory effect performed by PCR inhibitors is to carry out PCR positive control 
reactions. Spike-in experiments where an exogenous microorganism is added to 
your patient sample, to be co-extracted and amplified by another pair of primers 
and probe, could demonstrate inhibitors’ presence when no amplification  
occurs [41].
Other limitations of the technique are related to both the time of infection 
(acute phase) and the type of sample chosen. This relationship is directly associ-
ated with the success of the laboratory confirmation. It is known that the presence 
of the virus in the plasma, saliva, breast milk, and nasopharyngeal swab is short, 
which allows the detection of viral RNA for a limited time, and during the acute 
phase of the disease, it is calculated on average 3–7 days after the occurrence of 
the symptoms. On the other hand, urine and saliva biological samples are opti-
mal in the context of infant and newborn diagnosis due to low invasiveness and 
easy sample access [7, 10, 42–44]. In term of RNA detection, urine samples are 
described to present positivity from the fourth day until 29 days after the onset of 
symptoms [45], another time this sample opens the possibility of virus detection 
in longer times, even after the period of viremia. In adults, the biological sample 
that displays an increased period of viral persistence was semen, with cases where 
RNA detection occurred months after ZIKV infection. This raises the possibility 
that viral persistence could exist in both female and male genital tract (Figure 2) 
[8, 42, 46–48].
Apart of a positive RT-qPCR result for ZIKV, quantitative PCR offers the opportu-
nity to deliver viral copies relative to tissue milligrams or fluid milliliters. To calculate 
viral load is imperative to construct a standard curve, from a serial dilution from a 
Figure 2. 
Literature evidence on the average period of virus RNA positivity in different body fluids and serum 
immunoglobulins levels after symptoms onset. Bars following the timeline indicate sample and proper molecular 
test that should be used to investigate infection after viral exposition, and dashes represent virus load decrease. 
*Immunoglobulins development expected for a primary flavivirus infected patient. A secondary exposition 
should promote earlier and higher IgG serum titles with short and reduced IgM levels. **ZIKV detection in 
genital fluids without viremia suggests viral tropism and persistence in those organs.
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reference sample that was previously determined RNA copies or plaque forming units 
(PFU). Then, the sample result will be possible to extrapolate from a relative mea-
surement to an absolute quantification applied to a patient sample. This quantitative 
molecular diagnosis, in some pathologies (e.g., Hepatitis B and C, HIV, and herpes), 
has been already described as important indicators of health status and guide treat-
ment choices. In the case of ZIKV infection, viral load does not appear to be related 
with clinical adverse events in congenital infections [49] or general population [50], 
but it was important to demonstrate viral load in different biological samples. As 
shown in Figure 3, the amniotic fluid has the highest viral load when compared with 
other biological fluids (urine or blood). However, in the context of an epidemiological 
outbreak, blood and urine are the more accessible samples with a significantly higher 
amount of virus and prolonged RNA detection (Figure 2) in urine than blood. The 
placenta did not present a significant difference when compared to blood and urine.
However, as discussed before, potential ZIKV RNA viral mutation turns RT-qPCR 
methods not infallible. Viral genetic evolution raises the possibility that polymor-
phisms inside primer annealing site may generate false negative amplification 
reactions of the ZIKV genome targeted region. During 2015 ZIKV outbreak, there 
was six widely used in-house RT-qPCR methods for diagnostic [1, 51–53], and their 
suitability for detection of ZIKV Asian strain was reported by Corman et al. with 
clear differences in sensitivity between them [54]. Poor PCR sensitivity and low RNA 
viral load observed in patient samples can be one of the explanations for the reduced 
number of laboratory-confirmed cases during the last epidemics. Few RT-qPCR kits 
for ZIKV detection were commercially available, and high costs also limited their use 
and could be the other reason for lower confirmed cases, especially in most of the 
endemic countries [55]. Besides the small amount of proficient clinical laboratories, 
performance control of in-house methodologies continues to be a challenging task; 
therefore, constant interlaboratory control should be stimulated, and standardized 
reagents, suitable probes, and primers should be used whenever possible.
3.2 Immunoenzymatic assays for virus detection
3.2.1 NS1 tests
Another flavivirus laboratory test that has gained prominence is the detection of 
NS1 viral protein in the serum, which in turn reflects a viral infection during the acute 
Figure 3. 
ZIKV RNA viral load in different biological samples. Noninvasive biological samples urine presents a higher 
viral load than blood samples (**p-value < 0.001). AF viral load is the highest when compared with other 
maternal samples (***p-value < 0.0001). AF, amniotic fluid. CSF, cerebrospinal fluid. Data generated from 13 
placentas, 12 CSF, 6 fetal tissues, 4 AF, 24 urine, and 49 blood samples.
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phase [56]. Largely used during DENV outbreaks, it is based on NS1 protein secre-
tion by infected cells that reach high serum concentrations during periods of viral 
replication during flaviviruses and is considered an important acute phase biomarker 
for dengue fever. The assay format is suitable for use in routine laboratories around 
the world, allowing high-throughput testing in epidemic regions [31, 56]. Serological 
identification of ZIKV infections could also be maximized by parallel testing for IgM/
IgG and NS1. The limitation of this assay is related to cross-reactivity between Zika 
and other flaviviruses, once they display a high degree of homology around their viral 
proteins, especially with dengue [1]. However, serological tests are constantly improv-
ing in order to increase the specificity through the use NS1-based anti-ZIKV, and it 
has been recently shown to be more sensitive and highly specific for the serodiagnosis 
of ZIKV infections but has not yet been commercially available [31].
3.2.2 Immunohistochemistry
Immunohistochemistry is an important tool to evaluate vertical transmission 
(placenta infection). Through this, viral particles of ZIKV have already been detected 
in placental defense cells, known as Hofbauer cells. These cells are of fetal origin and 
have the ability to migrate, in areas that have contact with trophoblastic epithelium 
and vessels of the fetus. It is believed that ZIKV has an immune system evasion 
mechanism and Hofbauer cells are responsible for viral dissemination, facilitating 
their access to the fetal compartment besides being a viral reservoir [57]. Due to access 
to the fetal compartment, ZIKV gains open access to fetal layer where no more immu-
nological barrier could arrest their access to fetal central nervous system (CNS) [58].
ZIKV neuronal tropism was observed and described in affected fetus through 
necropsy studies. It was clearly demonstrated ZIKV antigens being expressed in 
large amounts in the brain with sporadic amounts of ZIKV antigens found in other 
fetal tissues, like liver, kidney, heart, and lung [59]. The opportunity to demonstrate 
CNS prolonged viral persistence was showed in a necropsy study conducted in a 
5-month infant deceased after ZIKV congenital infection, which occurred in the 
first trimester of pregnancy. In this case report, ZIKV was still present in the brain 
tissue with no evidence of inflammation or brain damage evolution [60].
3.3 Virus isolation
Virus isolation using cell culture or animals remains as an option for virus 
detection. Vertebrate or invertebrate cells (e.g., Aedes albopictus clone C6/36) can 
be used for ZIKV propagation from the biological sample. This methodology allows 
the identification of infectious particles and was used to evaluate the body fluid 
potential to transmit the virus, such as saliva, breast milk, and urine. Additionally, 
cellular propagation increases the sensitivity in low viral load samples; however, the 
condition of sample transport and storage can impact the test result. This seems to 
be even more important for ZIKV, which demonstrates reduced stability in fluids 
and tissues [61]. Due to the time required for virus propagation and the cell culture 
structure need, viral isolation is not used in the diagnostic routine.
4. Serology tests
4.1 ELISA tests
The considerable cross-reactivity between flavivirus antibodies is the major 
challenge for serological test development. In endemic areas, where dengue and 
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Zika viruses cocirculate besides several proposed ELISA tests, individuals previ-
ously exposed to other flaviviruses are not prevented to be misclassified. Another 
complication for patients experiencing a second flavivirus infection is a shorten IgM 
antibody response that could misdiagnose the time for acute infection [1].
This presents a diagnostic dilemma for patients living in regions in which flavivi-
ruses are endemic, and reliable diagnostic tools that are able to discriminate between 
primary and secondary ZIKV or DENV infections are urgently needed [1, 62, 63].
Although the precise period of onset and duration IgM class antibodies in 
response to ZIKV is not well defined, data known by other flaviviruses suggest that 
IgM for ZIKV should start to be detectable 7 days following infection, in the major-
ity of symptomatic patients (Figure 2). However, it has been recently reported in 
the literature that seroconversion may occur earlier for one-third of patients [1, 42]. 
While anti-ZIKV antibody titers decrease, IgM to ZIKV has a window of detection 
more than 12 weeks following infection for over 80% of individuals [42]. According 
to the modeling studies with other flaviviruses, including West Nile virus (WNV) 
and dengue (DENV), this serum persistence is consistent with the antibody 
responses following infection, suggesting that the mean time to IgM seronegativity 
ranges from 5 to 6 months [64, 65].
Apart from initial antibody response, IgG neutralizing antibodies (NA) nor-
mally develop after IgM response and should persist for years to decades following 
primary infection. It is believed that NA to ZIKV directed to a key epitope after 
infection should be highly specific in patients without prior exposure to flavivi-
ruses; however, NA specificity, in the setting of past exposure to a closely related 
flavivirus, such as DENV, once shares diverse antigenic determinants, decrease 
specificity to ZIKV epitopes [1].
Another tool that is being proposed in the context of outbreaks is rapid point of 
care (POC) tests which are based on the IgM/IgG immunochromatography assay. 
They should be used carefully and are normally interpreted as qualitative screening 
tests, and further serological investigations are needed. When they present a posi-
tive result, the patient samples should be sent for plaque reduction neutralization 
test (PRNT), or in the case of pregnant women, RT-qPCR is recommended [66, 67].
Special attention should be given to the risk group composed of newborns, 
where the immunoenzymatic serological test is extremely important to define con-
genital infection. ZIKV IgG antibody detection in a newborn may reflect maternal 
infection due to the passive transfer of this class of immunoglobulins. Based on 
other congenital infections, uninfected newborns display IgG levels that decline 
gradually in the first months of life, and this corresponds to the time of elimination 
of the antibody transmitted by the mother [68]. For this reason, tests to detect IgM 
are commonly used to confirm infection in the child, and in the context of flavivirus 
infection, only ZIKV was demonstrated to cross the placental and fetal immuno-
logical barriers [69, 70]. ZIKV IgM positivity in CSF, after congenital infection, was 
described as a reliable tool to discriminate fetal infection, and it characterized high 
risk for neuroinvasive disease [71].
4.2 Plaque reduction neutralization test (PRNT)
Until now, the unique reference standard for NA detection related to flaviviruses 
remains the plaque reduction neutralization test (PRNT). Although technically 
cumbersome, with several challenges: (1) long turnaround time of days to weeks; 
(2) requirement for live viral cultures; (3) technical-experience dependence; and 
(4) high degree of subjectivity, it offers the highest achievable level of specificity. 
This test initiates with a serial dilution of patient serum that is preincubated with 
live ZIKV or other closely related viruses (e.g., DENV), followed by deposition 
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onto a virus-susceptible cell monolayer. After proper incubation time, any resulting 
plaques suggest nonneutralized live virus and absence of specific antibodies. Those 
plaques are quantified and compared to plaques number obtained in culture wells 
containing virus-only in order to establish which serum dilution promotes 90% 
reduction in plaques occurrence in this patient sample (PRNT90). ZIKV and DENV 
PRNT90 titers are subsequently compared to define the specificity of the NAs [72]. 
Although the PRNT assay has a higher sensitivity than other tests such as hemag-
glutination and enzyme immunoassay and is more specific than other serological 
methods for the diagnosis, the limitation of this test is not discriminate between 
antibody classes and, especially in secondary flavivirus infections, cross-reactive 
neutralizing antibodies may contribute to virus neutralization [73]. In addition, 
PRNTs are time-consuming and laborious and are to be restricted to reference 
laboratories and research centers because they require the technical capacity to 
carry them out, as well as a complex laboratory structure [46].
5. Clinical context
Zika virus (ZIKV) infection is usually an asymptomatic or a mild symptomatic 
disease in adults, with maculopapular and pruritic rash, fever, conjunctivitis, joint 
pain, headache, and muscle pain [74]. However, infection during pregnancy may be 
transmitted to the fetus and causes severe systemic fetuses’ malformations, com-
prising the congenital Zika syndrome (CZS).
The clinical features of CZS have been described since 2015 Zika’s outbreak in 
Brazil. They can be divided into structural and functional components [75]. The 
structural components are cranial morphology, brain, and ocular anomalies, as 
well as congenital contractures [75]. The functional component is related to neuro-
logic sequelae [75]. Therefore, CZS may consist of (A) cranial morphology: severe 
microcephaly, overlapping cranial sutures, prominent occipital bone, redundant 
scalp skin, and neurologic impairment; (B) brain anomalies: thin cerebral cortices, 
abnormal gyral patterns, increased fluid spaces, subcortical calcifications, corpus 
callosum abnormalities, decreased white matter, and cerebellar hypoplasia; (C) 
ocular anomalies: macular scarring (Figure 4A), focal pigmentary retinal mottling 
(Figure 4B), and optic nerve hypoplasia or atrophy (Figure 4A); (D) congenital 
contractures: arthrogryposis and club feet; and (E) neurologic sequelae: marked 
early hypertonia, symptoms of extrapyramidal involvement, epilepsy, and irritabil-
ity [75–77]. Early recognition and referral to multidisciplinary care may result in a 
better outcome for each one of the abnormalities described.
Figure 4. 
(A) Right eye retinography showing macular (black arrowhead) and peripheral (black arrow) scarring and 
optic nerve hypoplasia (white arrow); (B) left eye retinography showing focal pigmentary retinal mottling 
(black arrow).
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Figure 5. 
Flowchart showing initially two clinical scenarios (symptomatic and asymptomatic pregnant women) 
and the different primary and secondary tests and results for Zika virus diagnosis during pregnancy. NAT: 
RT-qPCR nucleic acid test. IgM: Immunoglobulin M. US: Intrauterine ultrasound. PRNT: Plaques reduction 
neutralization test.
The diagnostic approach during prenatal care should be different in an endemic 
area and in a nonendemic area. Endemic area means residence in or travels to the 
affected area. In addition, in each of these two scenarios, the diagnosis is divided 
into symptomatic and asymptomatic pregnant women.
5.1 Endemic area (residence or travel)
5.1.1 Symptomatic pregnant women
The ZIKV infection is divided into acute and convalescent phases. The acute 
phase is within the first 7 days of the symptoms, and the convalescent phase is 
2–12 weeks after [78]. As shown in Figure 5, during the acute phase, the possible 
primary tests are the ZIKV RT-qPCR and the Immunoglobulin (Ig) M. The first one 
can be obtained from serum, saliva, urine, or amniotic fluid. When it is detected in 
the serum or saliva, it is confined to 5–7 days after onset of symptoms, and when 
it is detected in urine, it lasts up to 3 weeks after onset of illness. The evidence is 
lacking on the diagnostic accuracy of RT-qPCR of amniotic fluid and on the optimal 
time to perform amniocentesis [74]. The IgM is detectable ≥4 days after onset of 
illness [78]. In the convalescent phase, the primary test is IgM and the second test is 
plaque reduction neutralization test (PRNT). However, the Zika virus RT-qPCR can 
also be performed during this phase.
If the primary results are negative ZIKV RT-qPCR and negative ZIKV IgM 
(red flowchart in Figure 5), there is no evidence of virus detection, but an intra-
uterine ultrasound scan (US) should be done. If there are any fetal development 
abnormalities, serological tests for others congenital infections could be done and 
the pregnant woman should be referred to a specialized care. The possible congenital 
infections are toxoplasmosis, rubella, cytomegalovirus (CMV), herpes virus, parvo-
virus B19, varicella, and syphilis, known by the acronym TORCH’s syndrome (Sd). 
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The possible fetal abnormalities are microcephaly, intracranial calcifications, ocular 
lesions and calcifications, ventriculomegaly, abnormal sulcation and gyration, 
abnormal cortical development (lissencephaly), cerebral atrophy, callosal dysgen-
esis, cerebellar atrophy, brainstem hypoplasia, microphthalmia and arthrogryposis, 
intrauterine growth restriction, and evidence of placental insufficiency [74]. If there 
is absence of fetal abnormalities, the pregnant can follow routine antenatal care and 
it should be considered to repeat the US at 28–30 weeks [74].
If the primary results are negative ZIKV RT-qPCR and non-negative ZIKV IgM, 
the secondary test PRNT should be performed. It can be done for any other flavivirus 
that might be found in that geographic area [74]. If ZIKV PRNT ≤10 (white flowchart 
in Figure 5), there is no evidence of Zika virus infection. If ZIKV PRNT ≥10 and 
dengue virus PRNT ≥10 (blue flowchart in Figure 5), there is evidence of a flavivirus 
infection but no confirmation of a specific virus. Finally, if ZIKV PRNT ≥10 and den-
gue virus PRNT <10 (green flowchart in Figure 5), there is evidence of ZIKV infec-
tion. In any of the last two scenarios, the timing of infection cannot be determined.
If the primary result is positive ZIKV RT-qPCR (green flowchart in Figure 5), 
acute ZIKV infection is confirmed and US should be done. If there is any fetal abnor-
mality, the pregnant woman should be referred to a specialized care, and if there 
is no abnormality, routine antenatal care should be done, as well as a US follow-up 
every 4 weeks until birth [74, 79].
5.1.2 Asymptomatic pregnant women
In endemic area of residence or traveling, the pregnant woman with possible 
ZIKV exposure should be first tested at initiation of prenatal care and three times 
during pregnancy [67]. The primary tests should be ZIKV RT-qPCR and ZIKV IgM 
serology. If available, US should be considered for fetal morphology assessment. 
The possible results of the laboratory tests and US are described above.
5.2 Nonendemic area
The asymptomatic woman should follow the routine antenatal care. The symp-
tomatic woman should do the primary tests ZIKV RT-qPCR and ZIKV IgM serology. 
If available, US for fetal morphology assessment should be considered.
Additionally, the differential diagnosis is also crucial for the correct assessment 
and management of the disease. Signs of maternal disease, as well as intrauterine 
and neonatal findings, are similar in most of the TORCH’s congenital infections 
[75, 80]. Moreover, some genetic syndromes (Sd), such as Aicardi-Goutières Sd, 
pseudo-TORCH Sd, and mutations in the JAM3, NDE1, and ANKLE2 genes can also 
be in the differential diagnosis [75].
The main clinical findings in maternal TORCH infections include nonspecific 
signs, like fever, fatigue, malaise, headache, myalgia, arthralgia, lymphadenopathy, 
conjunctivitis, and making the ability to recognize the specific etiological agent dif-
ficult. Moreover, there are typical findings in some of these infections that can lead 
to the diagnosis. In herpes simplex virus infection, there is also painful genital ulcer, 
pruritus, and dysuria [80]. In primary syphilis infection, there is a firm, round, and 
painless chancre on external genitals and vagina, lasting 3–6 weeks [81]. In rubella, 
parvovirus B19, varicella, and ZIKV, cutaneous rash is an additional important sign 
[80, 82, 83]. The rash in rubella is maculopapular and usually progresses from the 
face to the body, fading within 2–4 days [80, 82, 83]. In parvovirus B19, the rash is 
also maculopapular, persisting until the 6th day and disappearing on the 7–9th day 
after the first appearance [80, 82, 83]. First, it occurs on the face, sparing nasal, 
and periorbital zones and second, on the trunk and extremities [83]. In varicella, it 
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is initially pruritic and maculopapular, following a vesicular phase until crushing 
occurs, usually about 5 days later [84]. Finally, the rash in ZIKV infection is pru-
ritic, descending, and maculopapular, beginning proximally and spreading to the 
extremities with resolution occurring within 1–4 days of onset [14, 74].
Nonspecific intrauterine US findings in TORCH infections are intrauterine 
growth restriction, abnormal fluid imbalance (ascites, hydrops, pericardial effu-
sion, pleural effusion, and oligo-polyhydramnios), hepatosplenomegaly and 
hepatic calcifications, echogenic bowel, echogenic kidneys, and limb deformities 
[80, 85]. Cerebral brain calcification, although relatively common in most of these 
infections, can be an important distinguishing factor due to its location [80, 85]. In 
congenital toxoplasmosis, the calcifications are diffuse and widely distributed, and 
in rubella, they are at basal ganglia [80, 85]. In CMV congenital infection, the cal-
cifications are usually punctate and periventricular or cortical [80, 85]. Conversely, 
in ZIKV, the calcifications are larger and denser, usually appearing at the gray and 
white matter junction [80, 86].
As well as seen with maternal clinical signs and intrauterine US findings, 
TORCH congenital infection can also produce a similar neonatal clinical presenta-
tion, although the features rarely occur simultaneously [87, 88]. The common 
clinical features include growth retardation, prematurity, jaundice, anemia, 
hepatosplenomegaly, microcephaly, cerebral calcifications, chorioretinitis, cata-
racts, microphthalmia, and others [87, 88]. However, clinical findings are more 
associated, although not exclusively, with a determined etiological agent. Cardiac 
lesions and deafness have been described in CMV and rubella congenital infections. 
Cicatricial skin lesions and limb hypoplasia are seen in varicella virus congenital 
infection [87]. Petechial or purpuric form exanthema (blueberry muffin spot) is 
typical of CMV infection [80, 82]. Chorioretinitis, hydrocephalus, and cerebral 
calcifications comprise the characteristic triad of congenital toxoplasmosis [89].
Finally, clinical signs of CZS can also be found in other TORCH infections. 
Cranial ZIKV morphology and brain anomalies can occur in congenital CMV infec-
tion [75]. Congenital contractures can appear in congenital rubella, varicella, and 
Coxsackie B infections [75]. Neurologic sequelae are seen in most TORCH infections 
[75]. Ocular anomalies, such as pigmentary mottling and chorioretinal scars, can 
manifest differently in each of these congenital infections. In rubella, the pigment 
mottling is usually diffused compared with the focal pigment mottling seen in Zika 
virus infection (Figure 4B) [77]. Chorioretinal lesions in toxoplasmosis can present 
with active exudative retinitis or regressed macular or peripapillary retinal scar [77]. 
In ZIKV congenital infection, chorioretinal lesions are atrophic and colobomatous-
like and are found in the macula or retinal periphery (Figure 4A) [77]. Optic nerve 
hypoplasia, commonly seen in ZIKV congenital infection, is seldom seen in rubella, 
toxoplasmosis, herpes, and CMV congenital infections [77].
6. Conclusions
Human clinical diagnosis of ZIKV infection in regions where other arboviruses 
circulate, mainly DENV and CHIKV, has become a daunting task; therefore, labora-
tory confirmation is crucial for conclusive diagnosis. Detection of virus genome 
by RT-qPCR is helpful and demonstrated to be a reliable tool; however, the limited 
window for virus detection, low viral load, and stability restricted the use of these 
methodologies. Antibody screening is also hampered by cross-reactivity among 
other flaviviruses.
Due to impact of ZIKV infection, especially for pregnant women, a confident 
ZIKV serology test is urgently needed, and this will promote a better prenatal 
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follow-up, especially in endemic areas. Nonetheless, as mentioned above, there are 
typical findings to aid the correct diagnosis and, thus, the appropriate management 
and counseling of the disease.
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